Opioid Use Disorder Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Agonist Drugs is the fastest growing sector, North America is the largest market

The Global Opioid Use Disorder (OUD) Drugs Market is projected to expand robustly from USD 3.89 Billion in 2025 to USD 6.81 Billion by 2031, at a Compound Annual Growth Rate of 9.78%. This market encompasses pharmaceutical formulations like buprenorphine, methadone, and naltrexone, which are vital for managing opioid dependence by alleviating withdrawal symptoms and reducing cravings. Market growth is primarily driven by the escalating prevalence of opioid addiction, coupled with substantial increases in government funding dedicated to medication-assisted treatment (MAT) programs.

The urgent need for effective therapeutic interventions is underscored by statistics showing a 536 percent rise in workplace overdose fatalities since 2011 by 2026. Moreover, the expanding adoption of evidence-based MAT models, combining behavioral therapy with pharmacotherapy, has significantly propelled demand, leading to over 650,000 individuals receiving OUD medications and contributing to a provisional 27 percent decrease in annual drug overdose deaths in the U.S. by 2024, emphasizing the market's critical role in public health improvement.

Market Drivers

Despite this progress, the market faces significant impediments, primarily from the persistent social stigma surrounding addiction treatment, which often discourages patients from seeking essential care and hinders public health initiatives. Furthermore, restrictive regulatory frameworks governing the distribution of controlled substances impose rigorous administrative burdens on healthcare providers and pharmacies, creating supply chain bottlenecks and resulting in geographic gaps in treatment availability, as evidenced by one in eight U.S. neighborhoods meeting pharmacy shortage criteria in 2025. Conversely, several key trends are actively reshaping the market: the rising adoption of long-acting injectable buprenorphine formulations is enhancing treatment adherence and continuity, exemplified by Sublocade's 15 percent revenue increase to $219 million in Q3 2025. Concurrently, the expansion of telehealth services for MAT delivery is critically widening patient access by removing logistical barriers and mitigating stigma, with companies like Bicycle Health securing $16.5 million in funding to scale virtual treatment services that have already reached over 40,000 patients.

Market Challenges

Despite this progress, the market faces significant impediments, primarily from the persistent social stigma surrounding addiction treatment, which often discourages patients from seeking essential care and hinders public health initiatives. Furthermore, restrictive regulatory frameworks governing the distribution of controlled substances impose rigorous administrative burdens on healthcare providers and pharmacies, creating supply chain bottlenecks and resulting in geographic gaps in treatment availability, as evidenced by one in eight U.S. neighborhoods meeting pharmacy shortage criteria in 2025. Conversely, several key trends are actively reshaping the market: the rising adoption of long-acting injectable buprenorphine formulations is enhancing treatment adherence and continuity, exemplified by Sublocade's 15 percent revenue increase to $219 million in Q3 2025. Concurrently, the expansion of telehealth services for MAT delivery is critically widening patient access by removing logistical barriers and mitigating stigma, with companies like Bicycle Health securing $16.5 million in funding to scale virtual treatment services that have already reached over 40,000 patients.

Market Trends

Despite this progress, the market faces significant impediments, primarily from the persistent social stigma surrounding addiction treatment, which often discourages patients from seeking essential care and hinders public health initiatives. Furthermore, restrictive regulatory frameworks governing the distribution of controlled substances impose rigorous administrative burdens on healthcare providers and pharmacies, creating supply chain bottlenecks and resulting in geographic gaps in treatment availability, as evidenced by one in eight U.S. neighborhoods meeting pharmacy shortage criteria in 2025. Conversely, several key trends are actively reshaping the market: the rising adoption of long-acting injectable buprenorphine formulations is enhancing treatment adherence and continuity, exemplified by Sublocade's 15 percent revenue increase to $219 million in Q3 2025. Concurrently, the expansion of telehealth services for MAT delivery is critically widening patient access by removing logistical barriers and mitigating stigma, with companies like Bicycle Health securing $16.5 million in funding to scale virtual treatment services that have already reached over 40,000 patients.

Key Market Players

• Indivior PLC
• Alkermes plc
• Braeburn Pharmaceuticals, Inc.
• Novartis AG
• Purdue Pharma L.P.
• Mallinckrodt Pharmaceuticals
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Lundbeck A/S
• Titan Pharmaceuticals, Inc.

Report Scope

In this report, the Global Opioid Use Disorder Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Opioid Use Disorder Drugs Market, by Drug Type:

• Agonist Drugs
• Antagonist Drugs
• Others

Opioid Use Disorder Drugs Market, by Route of Administration:

• Oral
• Parenteral
• Sublingual
• Nasal

Opioid Use Disorder Drugs Market, by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Opioid Use Disorder Drugs Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Opioid Use Disorder Drugs Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.